MW 321.76 Da, Purity >98%. Potent, cell-permeable, irreversible non-selective Cdc25 inhibitor. Induces cell cycle arrest at both G1 and G2/M phase. Shows antiproliferative effects against tumor cell lines (IC50 = 0.2-35 μM). Shows antitumor effects in vivo. .
AI604853, CDC25A, CDC25A2, CDC25A2 CAG isoform, CDC25HU2, Cdc 25B, Cdc 25C, Cdc25m2, Cell division cycle 25 homolog A (S. pombe), Cell division cycle 25 homolog B, Cell division cycle 25 homolog C, Cell division cycle 25A, Cell division cycle 25A isoform a, Cell division cycle 25A isoform b, Cell division cycle 25B, Cell division cycle 25B isoform 1, Cell division cycle 25B isoform 2, Cell division cycle 25B isoform 3, Cell division cycle 25B isoform 4, Cell division cycle 25B isoform 5, Cell division cycle 25C, Cell division cycle 25C protein, D9Ertd393e, Dual specificity phosphatase Cdc25A, Dual specificity phosphatase Cdc25B, Dual specificity phosphatase Cdc25C, EC 3.1.3.48, H4 K20 specific histone methyltransferase, H4-K20-HMTase, H4-K20-HMTase SETD8, Histone H4 K20 methyltransferase, Histone lysine N methyltransferase H4 lysine 20 specific, Histone-lysine N-methyltransferase SETD8, Lysine N-methyltransferase 5A, M-phase inducer phosphatase 1, M-phase inducer phosphatase 2, M-phase inducer phosphatase 3, MGC115549, MPIP1_HUMAN, MPIP2_HUMAN, MPIP3_HUMAN, Mitosis inducer CDC25, N-lysine methyltransferase SETD8, PPP1R60, PR-Set7, PR/SET domain containing protein 8, PR/SET domain-containing protein 07, PR/SET07, Phosphotyrosine phosphatase, Pr SET 7, PrSET7, SET 07, SET 8, SET domain containing (lysine methyltransferase) 8, SET domain containing 8, SET domain containing lysine methyltransferase 8, SET domain-containing protein 8, SETD 8, SETD8_HUMAN, protein phosphatase 1, regulatory subunit 60
MW 321.76 Da, Purity >98%. Potent, cell-permeable, irreversible non-selective Cdc25 inhibitor. Induces cell cycle arrest at both G1 and G2/M phase. Shows antiproliferative effects against tumor cell lines (IC50 = 0.2-35 μM). Shows antitumor effects in vivo. .
Soluble in ethanol to 50 mM.
Soluble in DMSO to 50 mM.
Potent, cell-permeable, irreversible non-selective Cdc25 inhibitor. Induces cell cycle arrest at both G1 and G2/M phase. Shows antiproliferative effects against tumor cell lines (IC50 = 0.2-35 μM). Shows antitumor effects in vivo.
The Cdc25 phosphatase family consisting of Cdc25A Cdc25B and Cdc25C plays key roles in controlling cell cycle progression. Cdc25A with a molecular mass of approximately 65 kDa is primarily located in the nucleus of proliferating cells. Cdc25B around 62 kDa can shuttle between the cytoplasm and nucleus and is often seen in various tissues including brain and testis. Cdc25C about 49 kDa mainly remains in the cytoplasm but translocates to the nucleus at specific cell cycle stages. KMT5A also known as SETD8 or Pr-SET7 is a histone methyltransferase with a molecular weight of approximately 41 kDa expressed in the nucleus of all proliferating cells.
These Cdc25 proteins activate cyclin-dependent kinases (CDKs) by dephosphorylating key amino acids promoting cell cycle progression through different phases such as G1 S and G2/M. They are not part of a major complex but interact with cell cycle regulators and checkpoints. KMT5A specifically monomethylates histone H4 at lysine 20 (H4K20me1) affecting chromatin structure and regulating gene expression. This modification influences DNA replication and repair mechanisms.
These proteins influence the cell cycle regulation and DNA damage response pathways. Cdc25 phosphatases interact closely with cyclin-CDK complexes driving cell cycle transitions. For example Cdc25A promotes G1/S transition in cooperation with CDK2. KMT5A is involved in DNA replication initiation and interacts with proteins like proliferating cell nuclear antigen (PCNA). It is also integral to damage response pathways ensuring genomic stability by interacting with replication licensing factors.
These targets have significant roles in cancer development and progression. Overexpression of Cdc25A and B is observed in various tumors linking them to malignancies such as breast and prostate cancer. They impact tumor progression by deregulating cell cycle checkpoints. Aberrant KMT5A expression and its influence on chromatin modification relate to disorders like tail chromosome instability syndrome. KMT5A’s interaction with proteins such as p53 connects it to tumor-suppressor pathways affected in cancer.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com